Abstract
Managed entry agreements (MEAs) have become a topical issue due to the increasing cost of new medicines and the presence of significant uncertainty at the time of making reimbursement decisions. There are uncertainties about clinical and economic evidence, fair prices and budget impact, as well as about the eligible patient population. Innovative solutions are needed to make new medicines
available to patients and to ensure the long-term financial sustainability of health care systems. This article outlines the use of MEAs in Estonia, Latvia and Lithuania as part of their pharmaceutical policy arsenal to improve access to new medicines.
available to patients and to ensure the long-term financial sustainability of health care systems. This article outlines the use of MEAs in Estonia, Latvia and Lithuania as part of their pharmaceutical policy arsenal to improve access to new medicines.
Original language | English |
---|---|
Pages | 27-30 |
Number of pages | 4 |
Volume | 22 |
No. | 1 |
Specialist publication | Eurohealth |
Publisher | Regional Office for Europe, World Health Organization |
Publication status | Published - 2016 |
Externally published | Yes |
Keywords*
- Managed Entry Agreements, Reimbursement, Pharmaceutical Policy, Estonia, Latvia, Lithuania
Field of Science*
- 3.3 Health sciences
Publication Type*
- 6. Other publications